
  
    
      
        Editorial_NNP note_NN
        A_DT commentary_NN on_IN this_DT article_NN can_MD be_VB found_VBN at_IN
        http_NN :_: /_NN /_NN www_NN ._. biomedcentral_NN ._. com_NN /_NN 1471_CD -_: 8219_CD /_NN 2_CD /_NN 5_CD
      
      
        Introduction_NNP
        Cardiovascular_NNP diseases_NNS ,_, a_DT major_JJ health_NN concern_NN in_IN
        industrialized_VBN countries_NNS [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ,_, include_VBP
        vasculopathies_NNS such_JJ as_IN atherosclerosis_NNS [_NN 5_CD ]_NN and_CC autoimmune_JJ
        vascular_NN diseases_NNS such_JJ as_IN lupus_JJ [_NN 6_CD ]_NN ,_, graft_NN versus_CC host_NN
        disease_NN [_NN 7_CD ]_NN ,_, and_CC systemic_JJ sclerosis_NN [_NN 8_CD ]_NN ._. Many_JJ factors_NNS
        are_VBP involved_VBN in_IN the_DT development_NN and_CC progression_NN of_IN these_DT
        diseases_NNS including_VBG lifestyle_NN (_( diet_NN ,_, smoking_NN ,_, and_CC lack_NN of_IN
        physical_JJ exercise_NN )_) ;_: genes_NNS ,_, and_CC environment_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._.
        Also_RB ,_, infectious_JJ agents_NNS ,_, including_VBG both_DT bacterial_JJ
        (_( Chlamydia_NNP )_) [_NN 9_CD 10_CD ]_NN ,_, and_CC viral_JJ (_( CMV_NNP )_) [_NN 11_CD 12_CD ]_NN ,_, have_VBP
        been_VBN implicated_VBN ._. CMV_NNP ,_, a_DT herpes_NNS virus_NN ,_, causes_NNS chronic_JJ
        asymptomatic_JJ infections_NNS in_IN immunocompetent_NN individuals_NNS ,_,
        termed_VBD latency_NN [_NN 13_CD ]_NN ._. However_RB ,_, in_IN situations_NNS of_IN
        immunocompromise_NN ,_, CMV_NNP is_VBZ reactivated_VBN ,_, which_WDT in_IN many_JJ cases_NNS
        leads_VBZ to_TO organ_NN failure_NN and_CC death_NN [_NN 13_CD ]_NN ._. Epidemiological_NNP
        reports_NNS indicate_VBP that_IN chronic_JJ CMV_NNP infections_NNS in_IN humans_NNS may_MD
        play_VB an_DT important_JJ role_NN in_IN pathogenesis_NNS of_IN vascular_NN diseases_NNS
        such_JJ as_IN atherosclerosis_NNS [_NN 14_CD ]_NN and_CC systemic_JJ sclerosis_NN [_NN 11_CD
        12_CD ]_NN ._. In_IN addition_NN ,_, a_DT recent_JJ report_NN [_NN 15_CD ]_NN revealed_VBD that_IN
        SSc_NNP autoantibodies_NNS bind_NN to_TO CMV_NNP late_JJ protein_NN UL_NNP 94_CD and_CC induce_VB
        apoptosis_NNS in_IN endothelial_NN cells_NNS therefore_RB implicating_VBG
        molecular_JJ mimicry_NN as_IN a_DT potential_JJ mechanism_NN accounting_NN for_IN
        the_DT link_NN between_IN SSc_NNP and_CC CMV_NNP ._.
        Here_RB we_PRP report_VBP that_IN MCMV_NNP infections_NNS of_IN gene-targeted_JJ
        mice_NNS lacking_VBG IFN-γR_NNP and_CC subjected_VBN to_TO whole_JJ body_NN irradiation_NN
        develop_VB vascular_NN lesions_NNS that_IN over_IN 4_CD months_NNS progress_NN to_TO
        severe_JJ vasculopathy_NN characterized_VBN by_IN significant_JJ neointima_NN
        formation_NN ,_, a_DT prominent_JJ feature_NN of_IN autoimmune_JJ vasculopathies_NNS
        in_IN humans_NNS ._. Furthermore_RB ,_, imunohistochemical_JJ analyses_NNS
        indicate_VBP the_DT presence_NN of_IN significant_JJ lymphohistiocytic_JJ
        infiltrate_VB in_IN the_DT adventitia_NN of_IN affected_VBN arteries_NNS
        containing_VBG both_DT T_NN and_CC B-_NNP lymphocytes_NNS ._. Neointima_NNP stained_JJ
        positive_NN for_IN both_DT -_: smooth_JJ muscle_NN actin_NN and_CC PCNA_NNP indicating_VBG
        proliferation_NN of_IN smooth_JJ muscle_NN cells_NNS possibly_RB mediated_JJ by_IN
        growth_NN factors_NNS TGF-β_NNP 
        1_CD ,_, PDGF-A_NNP and_CC PDGF-B_NNP ,_, while_IN TUNEL_NNP
        indicated_VBD apoptosis_NNS in_IN the_DT intimal_NN layer_NN in_IN affected_VBN
        arteries_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Mice_NNS
          All_DT experiments_NNS described_VBD in_IN this_DT study_NN confirm_VB with_IN
          "_'' The_DT guide_NN for_IN the_DT Care_NNP and_CC Use_NN of_IN Laboratory_NNP Animals_NNPS "_''
          published_VBN by_IN the_DT US_NNP National_NNP Institutes_NNPS of_IN Health_NNP (_( NIH_NNP
          Publication_NNP No_UH ._. 85_CD -_: 23_CD ,_, revised_VBD 1996_CD )_) ._. CD-_NNP 1_CD mice_NNS used_VBN for_IN
          generating_VBG the_DT MCMV_NNP stock_NN were_VBD purchased_VBN from_IN Charles_NNP
          River_NNP Laboratories_NNPS (_( Wilmington_NNP ,_, MA_NNP )_) ._. Experimental_NNP groups_NNS
          included_VBD :_: 1_LS )_) adult_NN ,_, immunocompetent_NN 129_CD S_NNP mice_NNS ,_, and_CC 2_LS )_)
          adult_NN B_NNP 6_CD ,_, 129_CD S_NNP IFN-γR-_NNP /_NN -_: mice_NNS ,_, both_DT obtained_VBN from_IN Jackson_NNP
          Laboratories_NNPS (_( Bar_NNP Harbor_NNP ,_, MN_NNP )_) ._. Food_NNP and_CC water_NN were_VBD
          provided_VBN 
          ad_NN libitum_NN ._. All_DT mice_NNS were_VBD housed_VBN in_IN
          hepa_NN filtered_VBN cages_NNS in_IN the_DT approved_VBN animal_NN facility_NN and_CC
          monitored_VBN daily_JJ for_IN the_DT development_NN of_IN clinical_JJ
          manifestations_NNS of_IN infection_NN ._.
        
        
          Preparation_NNP of_IN MCMV_NNP stock_NN and_CC infection_NN
          protocol_NN
          MCMV_NNP strain_NN Smith_NNP stock_NN was_VBD purchased_VBN from_IN American_NNP
          Type_NNP Tissue_NNP Collection_NNP (_( Rockville_NNP ,_, MD_NNP )_) This_DT virus_NN stock_NN
          had_VBD been_VBN propagated_JJ in_IN SC-_NNP 1_CD cells_NNS (_( mouse_NN embryo_NN
          fibroblast_NN cell_NN line_NN )_) ._. To_TO enhance_VB pathogenicity_NN ,_, the_DT
          virus_NN was_VBD passed_VBN three_CD times_NNS in_IN adult_NN immunocompetent_NN
          CD-_NNP 1_CD mice_NNS ,_, which_WDT were_VBD infected_VBN with_IN MCMV_NNP by_IN i_NNP ._. p_NN ._.
          injection_NN with_IN 5_CD x_SYM 10_CD 5_CD plaque_NN forming_VBG units_NNS (_( pfu_NN )_) ._. Two_CD
          weeks_NNS after_IN infection_NN mice_NNS were_VBD sacrificed_JJ ,_, salivary_JJ
          glands_NNS were_VBD collected_VBN ,_, and_CC virus_NN stock_NN was_VBD prepared_VBN as_IN a_DT
          10_CD %_NN weight_NN /_NN volume_NN homogenate_NN ._. Concentration_NNP of_IN virus_NN in_IN
          these_DT homogenates_NNS was_VBD determined_VBN by_IN a_DT standard_JJ plaque_NN
          assay_NN on_IN an_DT infected_JJ 3_CD T-_NNP 12_CD fibroblast_NN cell_NN line_NN ._. Final_NNP
          MCMV_NNP stock_NN contained_VBD 4_CD ._. 2_CD x_SYM 10_CD 6_CD PFUs_NNP /_NN ml_NN of_IN salivary_JJ gland_NN
          homogenate_NN ._. Control_NN animals_NNS were_VBD infected_VBN with_IN the_DT same_JJ
          concentration_NN of_IN salivary_JJ gland_NN homogenate_NN obtained_VBN from_IN
          control_NN uninfected_JJ CD-_NNP 1_CD mice_NNS ._.
        
        
          Experimental_NNP protocol_NN
          Two_CD months_NNS old_JJ mice_NNS were_VBD injected_VBN i_NNP ._. p_NN ._. with_IN either_DT
          MCMV_NNP or_CC control_VB salivary_JJ gland_NN homogenate_NN ._. Starting_VBG at_IN
          day_NN 15_CD after_IN infection_NN and_CC for_IN as_RB long_RB as_IN 6_CD months_NNS of_IN
          age_NN ,_, mice_NNS were_VBD sacrificed_JJ on_IN a_DT biweekly_RB basis_NN by_IN i_NNP ._. p_NN ._.
          injection_NN of_IN sodium_NN nembutal_NN ._. Hearts_NNPS and_CC abdominal_NN aortas_NNS
          were_VBD collected_VBN and_CC histopathological_JJ and_CC
          immunohistochemical_JJ analyses_NNS were_VBD performed_VBN ._. To_TO both_DT
          accelerate_VB the_DT development_NN of_IN vascular_NN pathology_NN and_CC to_TO
          deepen_NN the_DT immunocompromised_JJ state_NN ,_, these_DT mice_NNS were_VBD
          irradiated_VBN with_IN a_DT sublethal_NN dose_NN of_IN gamma_NN radiation_NN (_( 300_CD
          Rads_NNP )_) at_IN 4_CD months_NNS of_IN age_NN ._. Tissue_NNP sections_NNS were_VBD coded_VBN and_CC
          scoring_VBG was_VBD performed_VBN in_IN a_DT blinded_JJ fashion_NN ._.
        
        
          Histology_NNP
          H_NNP &_CC E_NNP ,_, Movat_NNP trichrome_NN ,_, and_CC Verhoeff_NNP van_NN Gieson_NNP ,_,
          staining_VBG was_VBD performed_VBN on_IN 4_CD μm_NN sections_NNS of_IN aortas_NNS fixed_VBN
          for_IN 16_CD hours_NNS in_IN neutral_JJ buffered_JJ formalin_NN (_( 10_CD %_NN )_) ,_, and_CC
          embedded_VBN in_IN paraffin_NN ._.
        
        
          Antibodies_NNP
          Polyclonal_NNP antibodies_NNS specific_JJ for_IN CD_NNP 4_CD ,_, CD_NNP 8_CD ,_, γ_NN /_NN δ-_NN TCR_NNP ,_,
          TGF-β_NNP 
          1_CD ,_, PDGF-A_NNP ,_, PDGF-B_NNP ,_, MCP-_NNP 1_CD and_CC
          polyclonal_NN antibody_NN to_TO PCNA_NNP were_VBD purchased_VBN from_IN Santa_NNP
          Cruz_NNP Biotechnology_NNP Inc_NNP ._. ,_, (_( Santa_NNP Cruz_NNP ,_, CA_NNP )_) ._. Polyclonal_NNP
          antibody_NN to_TO B-_NNP lymphocyte_NN marker_NN (_( B-_NNP 220_CD )_) was_VBD purchased_VBN
          from_IN Caltag_NNP Laboratories_NNPS (_( Burlingame_NNP ,_, CA_NNP )_) ._. Monoclonal_NNP
          antibody_NN specific_JJ for_IN α-smooth_JJ muscle_NN actin_NN (_( clone_NN 1_CD A_DT 4_LS )_)
          was_VBD purchased_VBN from_IN Sigma_NNP (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._.
        
        
          Immunohistochemical_NNP analysis_NN
          Tissues_NNPS were_VBD collected_VBN ,_, fixed_VBN in_IN formalin_NN ,_, and_CC
          embedded_VBN in_IN paraffin_NN ._. After_IN deparaffinizing_VBG and_CC two_CD
          5_CD -_: minute_NN washes_NNS in_IN PBS_NNP ,_, the_DT sections_NNS were_VBD blocked_VBN for_IN 20_CD
          minutes_NNS with_IN a_DT solution_NN of_IN 2_CD %_NN unconjugated_JJ goat_NN
          anti-mouse_JJ IgG_NNP in_IN 1_CD x_SYM PBS_NNP ._. Indicated_NNP dilutions_NNS of_IN the_DT
          primary_JJ antibodies_NNS were_VBD added_VBN to_TO the_DT slides_NNS and_CC incubated_JJ
          for_IN 2_CD hours_NNS at_IN room_NN temperature_NN followed_VBN by_IN two_CD 5_CD -_: minute_NN
          washes_NNS with_IN PBS_NNP ._. Biotinylated_NNP secondary_JJ IgG_NNP diluted_VBD 1_CD :_: 100_CD
          was_VBD added_VBN to_TO the_DT slides_NNS and_CC incubated_JJ for_IN 30_CD minutes_NNS ._.
          After_IN two_CD additional_JJ 5_CD -_: minute_NN PBS_NNP washes_NNS ,_, the_DT tissue_NN
          sections_NNS were_VBD treated_VBN with_IN a_DT 3_CD %_NN solution_NN of_IN hydrogen_NN
          peroxide_NN to_TO quench_NN endogenous_JJ peroxidase_NN activity_NN ._. After_IN
          two_CD additional_JJ 5_CD -_: minute_NN washes_NNS ,_, the_DT slides_NNS were_VBD incubated_JJ
          for_IN 30_CD minutes_NNS in_IN the_DT solution_NN containing_VBG the_DT
          avidin-biotin-peroxidase_JJ complex_NN ._. Diaminobenzidine_NNP /_NN H_NNP 
          2_CD O_NNP 
          2_CD substrate_NN was_VBD allowed_VBN to_TO react_VB with_IN
          the_DT peroxidase_NN labeled_VBD tissue_NN sections_NNS for_IN 20_CD minutes_NNS ._.
          After_IN two_CD 1_CD -_: minute_NN rinses_NNS in_IN distilled_VBN water_NN ,_, the_DT tissue_NN
          sections_NNS were_VBD counterstained_JJ with_IN hematoxilin_NN ,_, cleared_VBD
          and_CC dehydrated_JJ by_IN successive_JJ gradations_NNS through_IN 70_CD %_NN ,_, 95_CD %_NN ,_,
          and_CC 100_CD %_NN ethanol_NN followed_VBN by_IN a_DT final_JJ passage_NN in_IN xylene_NN ._.
          The_DT slides_NNS were_VBD mounted_VBN and_CC analyzed_VBN by_IN bright_JJ field_NN
          microscopy_NN ._.
        
        
          Tunel_NNP
          Animals_NNS were_VBD sacrificed_JJ and_CC tissues_NNS collected_VBN and_CC
          processed_VBN as_IN described_VBN for_IN immunohistochemistry_NN ._. TUNEL_NNP
          assay_NN was_VBD performed_VBN utilizing_VBG a_DT kit_NN for_IN 
          in_IN situ_NN detection_NN of_IN apoptosis_NNS ,_,
          Oncogene_NNP ,_, (_( Cambridge_NNP ,_, MA_NNP )_) ,_, according_VBG to_TO manufacturer_NN 's_POS
          instructions_NNS ._. Briefly_NNP ,_, 5_CD μm_NN sequential_NN sections_NNS were_VBD
          deparaffinized_JJ and_CC fixed_VBN with_IN 4_CD %_NN paraformaldehyde_NN for_IN 20_CD
          minutes_NNS at_IN room_NN temperature_NN followed_VBN by_IN 30_CD minute_NN wash_NN in_IN
          PBS_NNP ._. After_IN a_DT 5_CD minute_NN rinse_NN with_IN PBS_NNP ,_, 50_CD μl_NN of_IN TUNEL_NNP
          reaction_NN mixture_NN was_VBD added_VBN to_TO tissue_NN sections_NNS and_CC
          incubated_JJ in_IN humidified_JJ chamber_NN for_IN 60_CD minutes_NNS at_IN 37_CD °_NN C_NNP
          followed_VBN by_IN three_CD 5_CD minute_NN rinses_NNS in_IN PBS_NNP and_CC directly_RB
          analyzed_VBD under_IN the_DT microscope_NN ._.
        
      
      
        Results_NNS
        
          Neointima_NNP formation_NN triggered_VBN by_IN MCMV_NNP
          infection_NN
          Both_DT immunocompetent_NN 129_CD S_NNP and_CC immunodeficient_NN
          IFN-γR-_NNP /_NN -_: mice_NNS were_VBD infected_VBN by_IN i_NNP ._. p_NN ._. injection_NN at_IN age_NN 2_CD
          months_NNS with_IN either_DT 1_CD x_SYM 10_CD 5_CD or_CC 5_CD x_SYM 10_CD 4_CD pfus_JJ of_IN MCMV_NNP stock_NN ._.
          At_IN 1_CD x_SYM 10_CD 5_CD pfus_JJ /_NN mouse_NN ,_, 90_CD %_NN of_IN IFN-γR-_NNP /_NN -_: mice_NNS died_VBD with_IN
          necrotizing_VBG hepatitis_NN between_IN days_NNS 5_CD -_: 10_CD ._. Reducing_VBG the_DT
          dose_NN of_IN MCMV_NNP to_TO 5_CD x_SYM 10_CD 4_CD pfu_NN resulted_VBD in_IN lower_JJR mortality_NN
          rates_NNS (_( 30_CD %_NN )_) ._. In_IN the_DT immunocompetent_NN group_NN no_DT deaths_NNS
          occurred_VBD at_IN either_DT dose_NN of_IN MCMV_NNP ._. Surviving_VBG mice_NNS that_WDT
          received_VBD either_DT dose_NN of_IN virus_NN developed_VBD perivascular_NN
          mononuclear_NN cellular_JJ infiltrates_NNS in_IN a_DT number_NN of_IN organs_NNS
          including_VBG lungs_NNS ,_, kidneys_NNS ,_, and_CC salivary_JJ glands_NNS ._. Vascular_NNP
          disease_NN in_IN the_DT IFN-γR-_NNP /_NN -_: group_NN of_IN mice_NNS began_VBD with_IN
          development_NN of_IN an_DT inflammatory_JJ infiltrate_VB in_IN the_DT
          adventitia_NN of_IN aortas_NNS 3_CD -_: 4_CD weeks_NNS after_IN infection_NN in_IN 30_CD %_NN of_IN
          animals_NNS (_( Table_NNP 1_LS )_) (_( Fig_NNP ._. 1_LS A_DT )_) ._. This_DT infiltrate_VB was_VBD
          comprised_VBN predominantly_RB of_IN lymphohistiocytic_JJ cells_NNS (_( Fig_NNP ._.
          1_LS A_DT )_) ._. The_DT vascular_NN disease_NN progressed_VBD over_IN a_DT time_NN course_NN
          of_IN 4_CD months_NNS and_CC affected_VBN between_IN 50_CD and_CC 65_CD %_NN of_IN animals_NNS
          (_( Table_NNP 1_LS )_) ._. In_IN the_DT group_NN of_IN IFN-γR-_NNP /_NN -_: mice_NNS receiving_VBG
          sublethal_NN (_( 300_CD Rads_NNP )_) whole_JJ body_NN irradiation_NN 2_CD months_NNS
          after_IN infection_NN all_DT examined_VBD animals_NNS exhibited_VBN vascular_NN
          pathology_NN (_( Table_NNP 1_LS )_) ._. Animals_NNS appeared_VBD healthy_JJ and_CC all_DT
          survived_VBD whole_JJ body_NN irradiation_NN ._. In_IN the_DT immunocompetent_NN
          group_NN of_IN animals_NNS these_DT infiltrates_NNS were_VBD cleared_VBN by_IN 8_CD
          weeks_NNS after_IN infection_NN and_CC from_IN that_DT point_NN these_DT animals_NNS
          were_VBD histologically_RB indistinguishable_JJ from_IN the_DT uninfected_JJ
          group_NN ._. On_IN the_DT contrary_NN ,_, in_IN the_DT IFN-γR-_NNP /_NN -_: mice_NNS infected_VBN
          with_IN MCMV_NNP ,_, vascular_NN disease_NN progressed_VBD to_TO the_DT formation_NN
          of_IN neointima_NN in_IN aortas_NNS by_IN 4_CD months_NNS of_IN age_NN ,_, (_( Fig_NNP ._. 1_LS B_NNP ,_, C_NNP ,_, D_NNP )_) ._.
          Verhoeff-van_NNP Gieson_NNP staining_VBG indicated_VBN the_DT focal_JJ
          destruction_NN of_IN aortic_JJ elastic_JJ fibrils_NNS in_IN addition_NN to_TO
          intimal_NN thickening_VBG (_( Fig_NNP ._. 1_LS D_NNP )_) Controls_NNP in_IN experiments_NNS
          using_VBG IFN-γR-_NNP /_NN -_: mice_NNS included_VBD :_: 1_LS )_) uninfected_JJ animals_NNS ,_, 2_LS )_)
          mice_NNS that_WDT were_VBD exposed_VBN only_RB to_TO the_DT whole_JJ body_NN irradiation_NN
          and_CC 3_LS )_) mice_NNS that_WDT received_VBD only_RB MCMV_NNP ._. Histopathological_NNP
          analysis_NN of_IN abdominal_NN aortas_NNS collected_VBN from_IN transgenic_JJ ,_,
          infected_JJ and_CC irradiated_JJ animals_NNS revealed_VBD severe_JJ
          vasculitis_NNS characterized_VBN by_IN significant_JJ inflammatory_JJ
          infiltrate_VB in_IN the_DT adventitia_NN and_CC media_NNS (_( Table_NNP 2_LS )_) ,_, (_( Fig_NNP ._.
          2_LS )_) ._. At_IN the_DT same_JJ time_NN hearts_NNS showed_VBD no_DT signs_NNS of_IN disease_NN
          (_( data_NNS not_RB shown_VBN )_) ._. Verhoeff-van_NNP Gieson_NNP (_( Fig_NNP ._. 2_LS C_NNP )_) and_CC Movat_NNP
          pentachrome_NN (_( Fig_NNP ._. 2_LS D_NNP )_) staining_VBG indicated_VBN the_DT focal_JJ
          destruction_NN of_IN elastic_JJ tissue_NN ,_, as_RB well_RB as_IN potential_JJ
          trafficking_NN of_IN the_DT infiltrating_VBG cells_NNS through_IN these_DT
          breaks_NNS in_IN the_DT elastica_NN ._. The_DT extent_NN of_IN vascular_NN damage_NN in_IN
          all_DT mice_NNS from_IN this_DT group_NN was_VBD similar_JJ ._. The_DT most_RBS striking_JJ
          feature_NN of_IN the_DT MCMV_NNP induced_VBD vascular_NN disease_NN was_VBD the_DT
          formation_NN of_IN neointima_NN in_IN aortas_NNS of_IN MCMV_NNP infected_JJ
          immunodeficient_NN mice_NNS after_IN irradiation_NN (_( Table_NNP 2_LS )_) ,_, (_( Fig_NNP
          2_LS )_) ._. At_IN the_DT same_JJ time_NN there_EX was_VBD no_DT vascular_NN pathology_NN in_IN
          any_DT of_IN the_DT control_NN groups_NNS (_( Table_NNP 2_LS )_) (_( Fig_NNP 2_CD A_DT )_) ._.
          Verhoeff-van_NNP Gieson_NNP staining_VBG of_IN aortas_NNS collected_VBN from_IN
          IFN-γR-_NNP /_NN -_: mice_NNS 30_CD days_NNS after_IN irradiation_NN (_( not_RB shown_VBN )_) and_CC
          IFN-γR-_NNP /_NN -_: mice_NNS 60_CD days_NNS after_IN irradiation_NN (_( Fig_NNP ._. 2_LS )_)
          indicated_VBD that_IN the_DT intimal_NN vascular_NN lesion_NN induced_VBN by_IN
          MCMV_NNP infection_NN was_VBD characterized_VBN by_IN collagen_NN deposition_NN
          and_CC smooth_JJ muscle_NN proliferation_NN ._. We_PRP utilized_JJ monoclonal_NN
          antibody_NN specific_JJ for_IN α-_NN SMA_NNP ,_, a_DT marker_NN for_IN myofibroblast_NN
          cells_NNS ,_, and_CC found_VBD that_DT neointima_NN seen_VBN in_IN the_DT aortas_NNS of_IN
          MCMV_NNP infected_JJ experimental_JJ animals_NNS contained_VBD
          myofibroblasts_NNS ._. (_( Fig_NNP ._. 3_LS )_) ._.
        
        
          Immunohistochemical_NNP characterization_NN of_IN immune_JJ
          response_NN to_TO MCMV_NNP infection_NN
          Immunohistochemical_NNP characterization_NN of_IN the_DT
          inflammatory_JJ infiltrate_VB seen_VBN in_IN the_DT adventitia_NN and_CC media_NNS
          of_IN the_DT affected_VBN aortas_NNS revealed_VBD both_DT helper_NN T-_NNP lymphocytes_NNS
          (_( CD_NNP 4_CD +_NN )_) (_( Fig_NNP ._. 4_LS B_NNP )_) and_CC cytotoxic_JJ T-_NNP lymphocytes_NNS (_( CD_NNP 8_CD +_NN )_)
          (_( Fig_NNP ._. 4_LS C_NNP )_) throughout_IN the_DT lesion_NN ._. Since_IN one_CD of_IN the_DT
          characteristics_NNS of_IN autoimmune_JJ vasculopathies_NNS is_VBZ the_DT
          appearance_NN of_IN high_JJ numbers_NNS of_IN γ_NN /_NN δ-_NN TCR_NNP [_NN 16_CD ]_NN bearing_NN
          cells_NNS ,_, we_PRP studied_VBD this_DT cell_NN type_NN in_IN our_PRP$ model_NN of_IN vascular_NN
          disease_NN ._. Results_NNS from_IN these_DT experiments_NNS revealed_VBD a_DT large_JJ
          number_NN of_IN γ_NN /_NN δ-_NN TCR_NNP bearing_NN lymphocytes_NNS throughout_IN the_DT
          lesion_NN (_( Fig_NNP ._. 4_LS D_NNP )_) ._. We_PRP also_RB investigated_VBD the_DT presence_NN of_IN
          B-_NNP lymphocytes_NNS in_IN the_DT vascular_NN lesion_NN of_IN MCMV_NNP infected_JJ
          mice_NNS ._. While_IN T-_NNP lymphocytes_NNS were_VBD identified_VBN throughout_IN the_DT
          lesion_NN these_DT cells_NNS were_VBD mostly_RB found_VBN in_IN small_JJ follicles_NNS
          (_( Fig_NNP ._. 4_LS A_DT )_) ._.
        
        
          Investigation_NNP of_IN the_DT role_NN of_IN cytokines_NNS and_CC growth_NN
          factors_NNS
          Growth_NN factors_NNS possibly_RB responsible_JJ for_IN the_DT neointimal_NN
          proliferation_NN were_VBD studied_VBN based_VBN on_IN their_PRP$ putative_JJ
          importance_NN in_IN autoimmune_JJ vasculopathies_NNS in_IN humans_NNS ._.
          Immunohistochemical_NNP analysis_NN indicated_VBD a_DT significant_JJ
          overproduction_NN of_IN TGF-β_NNP 
          1_CD ,_, PDGF-A_NNP ,_, and_CC PDGF-B_NNP in_IN the_DT MCMV_NNP
          induced_VBD intimal_NN lesion_NN (_( Fig_NNP ._. 5_LS )_) ._. While_IN TGF-β_NNP 1_CD and_CC PDGF-A_NNP
          immunoreactivity_NN in_IN affected_VBN arteries_NNS is_VBZ localized_VBN to_TO all_DT
          three_CD layers_NNS (_( intima_NN ,_, media_NNS ,_, adventitia_NN )_) (_( Fig_NNP ._. 5_LS Band_NNP 5_CD D_NNP )_) ,_,
          PDGF-B_NNP staining_VBG is_VBZ localized_VBN to_TO the_DT media_NNS and_CC neointima_NN
          (_( Fig_NNP ._. 5_LS F_NN )_) ._. MCP-_NNP 1_CD ,_, a_DT chemokine_NN that_WDT has_VBZ been_VBN implicated_VBN in_IN
          pathogenesis_NNS of_IN several_JJ autoimmune_JJ vascular_NN diseases_NNS
          including_VBG SSc_NNP ,_, was_VBD noted_VBN in_IN the_DT adventitia_NN and_CC media_NNS of_IN
          affected_VBN arteries_NNS (_( Fig_NNP ._. 6_CD )_) ._. We_PRP did_VBD not_RB detect_VB MCP-_NNP 1_CD
          positive_JJ staining_VBG in_IN neointima_NN (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Role_NNP of_IN apoptosis_NNS and_CC proliferation_NN
          Further_RB ,_, we_PRP investigated_VBD the_DT role_NN of_IN apoptosis_NNS and_CC
          proliferation_NN in_IN vascular_NN pathology_NN triggered_VBN by_IN MCMV_NNP
          infection_NN of_IN immunosuppressed_JJ mice_NNS ._. 
          In_IN situ_NN TUNEL_NNP revealed_VBD positive_JJ
          staining_VBG in_IN the_DT intimal_NN layer_NN of_IN affected_VBN aortas_NNS (_( Fig_NNP
          7_CD A_DT )_) ._. In_IN addition_NN ,_, a_DT small_JJ portion_NN of_IN infiltrating_VBG
          inflammatory_JJ cells_NNS stained_JJ positive_NN by_IN TUNEL_NNP (_( Fig_NNP ._. 7_CD B_NNP )_) ._.
          Smooth_NNP muscle_NN /_NN myofibroblast_NN cells_NNS forming_VBG the_DT neointima_NN
          did_VBD not_RB reveal_VB any_DT cells_NNS positive_JJ by_IN TUNEL_NNP (_( Fig_NNP ._. 7_CD A_DT )_) ._.
          Immunohistochemical_NNP staining_VBG for_IN PCNA_NNP was_VBD used_VBN to_TO
          identify_VB cell_NN proliferation_NN ._. The_DT majority_NN of_IN cells_NNS in_IN the_DT
          neointima_NN (_( Fig_NNP ._. 7_CD Cand_NNP Fig_NNP ._. 8_CD )_) ,_, as_RB well_RB as_IN infiltrating_VBG
          inflammatory_JJ cells_NNS (_( Fig_NNP ._. 7_CD Dand_NNP FIG_NNP ._. 8_CD )_) ,_, exhibit_NN
          immunoreactivity_NN for_IN PCNA_NNP ,_, indicating_VBG active_JJ
          proliferation_NN ._.
        
      
      
        Discussion_NNP
        The_DT major_JJ finding_NN of_IN this_DT study_NN is_VBZ the_DT formation_NN of_IN
        neointima_NN associated_VBN with_IN MCMV_NNP infection_NN in_IN
        immunocompromised_JJ mice_NNS ._. The_DT disease_NN described_VBD in_IN our_PRP$ study_NN
        resembles_VBZ pathological_JJ processes_VBZ seen_VBN in_IN other_JJ autoimmune_JJ
        vasculopathies_NNS ._. However_RB ,_, it_PRP is_VBZ important_JJ to_TO note_VB that_IN while_IN
        there_EX are_VBP undoubtedly_RB autoimmune_JJ aspects_NNS of_IN
        atherosclerosis_NNS ,_, this_DT issue_NN is_VBZ still_RB under_IN debate_NN [_NN 17_CD ]_NN ._.
        The_DT formation_NN of_IN neointima_NN characteristic_NN of_IN the_DT
        vasculopathy_NN in_IN autoimmune_JJ diseases_NNS by_IN this_DT approach_NN has_VBZ ,_,
        to_TO our_PRP$ knowledge_NN ,_, not_RB been_VBN previously_RB reported_VBN ._. While_IN MCMV_NNP
        vasculitis_NNS in_IN IFN-γR-_NNP /_NN -_: mice_NNS has_VBZ been_VBN previously_RB reported_VBN [_NN
        18_CD ]_NN ,_, that_DT study_NN does_VBZ not_RB focus_VB on_IN intimal_NN proliferation_NN ._.
        In_IN our_PRP$ experimental_JJ conditions_NNS we_PRP were_VBD able_JJ to_TO increase_VB
        yield_NN from_IN 62_CD %_NN affected_VBD animals_NNS in_IN IFN-γR-_NNP /_NN -_: mice_NNS infected_VBN
        with_IN MCMV_NNP to_TO 100_CD %_NN by_IN including_VBG whole_JJ body_NN irradiation_NN of_IN
        chronically_RB infected_JJ IFN-γR-_NNP /_NN -_: mice_NNS (_( Table_NNP 1_LS )_) ._. In_IN addition_NN ,_,
        a_DT striking_JJ increase_NN in_IN the_DT severity_NN of_IN intimal_NN lesions_NNS was_VBD
        noted_VBN in_IN irradiated_JJ mice_NNS (_( Table_NNP 2_LS )_) ._. We_PRP propose_VBP that_IN there_EX
        are_VBP two_CD possible_JJ explanations_NNS for_IN the_DT increase_NN in_IN both_DT the_DT
        number_NN of_IN affected_VBN animals_NNS ,_, as_RB well_RB as_IN increase_NN in_IN the_DT
        severity_NN of_IN vascular_NN disease_NN in_IN MCMV_NNP infected_JJ IFN-γR-_NNP /_NN -_:
        mice_NNS receiving_VBG whole_JJ body_NN irradiation_NN treatment_NN ._. First_LS ,_,
        sublethal_NN irradiation_NN additionally_RB immunosuppresses_NNS the_DT
        animals_NNS allowing_VBG unlimited_JJ replication_NN of_IN MCMV_NNP which_WDT may_MD
        lead_VB to_TO direct_VB viral_JJ damage_NN ._. Second_JJ ,_, the_DT immune_JJ system_NN
        after_IN recovering_VBG from_IN effects_NNS of_IN radiation_NN (_( reconstitution_NN )_)
        contains_VBZ large_JJ number_NN of_IN MCMV_NNP specific_JJ CTLs_NNP that_WDT may_MD be_VB
        capable_JJ of_IN inducing_VBG intimal_NN pathology_NN while_IN attempting_VBG to_TO
        clear_VB the_DT infection_NN ._.
        CMV_NNP infections_NNS have_VBP been_VBN implicated_VBN in_IN a_DT number_NN of_IN
        vascular_NN diseases_NNS ._. CMV_NNP invades_VBZ the_DT vascular_NN endothelium_NN
        with_IN the_DT development_NN of_IN both_DT latency_NN and_CC intermittent_JJ
        shedding_NN of_IN the_DT virus_NN to_TO distal_NN tissues_NNS ,_, often_RB by_IN
        detachment_NN of_IN infected_JJ endothelial_NN cells_NNS ._. In_IN
        immunocompetent_NN individuals_NNS CMV_NNP infections_NNS are_VBP of_IN chronic_NN
        or_CC latent_NN type_NN and_CC are_VBP usually_RB not_RB associated_VBN with_IN
        clinically_RB detectable_JJ disease_NN ._. In_IN immunocompromised_JJ
        patients_NNS such_JJ as_IN neonates_NNS ,_, transplant_NN recipients_NNS and_CC
        patients_NNS with_IN AIDS_NNP ,_, CMV_NNP infections_NNS are_VBP a_DT leading_VBG cause_NN of_IN
        organ_NN failure_NN and_CC death_NN ._. Nonetheless_RB ,_, the_DT mechanisms_NNS of_IN CMV_NNP
        reactivation_NN and_CC induction_NN of_IN vascular_NN lesions_NNS are_VBP not_RB well_RB
        understood_VBN ._. Clinical_NNP and_CC epidemiological_JJ studies_NNS strongly_RB
        suggest_VBP the_DT association_NN of_IN CMV_NNP infection_NN in_IN the_DT progression_NN
        of_IN numerous_JJ vascular_NN diseases_NNS ,_, including_VBG atherosclerosis_NNS [_NN
        16_CD 17_CD 18_CD 19_CD 20_CD ]_NN ,_, rapidly_RB progressive_JJ coronary_JJ artery_NN
        disease_NN ,_, endothelialitis_NNS in_IN heart_NN transplant_NN recipients_NNS [_NN
        21_CD 22_CD 23_CD 24_CD ]_NN ,_, coronary_JJ restenosis_NNS [_NN 25_CD 26_CD ]_NN ,_, and_CC
        inflammatory_JJ aortic_JJ disease_NN [_NN 27_CD 28_CD ]_NN as_RB well_RB as_IN SSc_NNP [_NN 11_CD
        12_CD ]_NN ._. We_PRP attempted_VBD to_TO reproduce_VB the_DT endpoint_NN of_IN such_JJ
        diseases_NNS by_IN using_VBG immunosupression_NN and_CC CMV_NNP infection_NN ,_,
        allowing_VBG us_PRP to_TO investigate_VB cellular_JJ and_CC molecular_JJ events_NNS
        leading_VBG to_TO this_DT pathology_NN ._. While_IN SSc_NNP is_VBZ an_DT autoimmune_JJ
        disease_NN affecting_VBG microvasculature_NN ,_, some_DT recent_JJ studies_NNS
        also_RB described_VBD increased_VBN incidence_NN of_IN vascular_NN pathology_NN in_IN
        the_DT large_JJ arterial_NN vessels_NNS of_IN SSc_NNP patients_NNS [_NN 29_CD 30_CD 31_CD ]_NN ._.
        However_RB ,_, it_PRP is_VBZ still_RB unclear_JJ if_IN macro_NN vascular_NN pathology_NN is_VBZ
        a_DT primary_JJ feature_NN of_IN SSc_NNP or_CC an_DT indirect_JJ effect_NN of_IN some_DT of_IN
        the_DT downstream_JJ events_NNS related_VBN to_TO this_DT disease_NN ._.
        Inoculation_NNP of_IN immunocompetent_NN mice_NNS with_IN MCMV_NNP causes_NNS
        persistent_JJ productive_JJ infection_NN in_IN salivary_JJ glands_NNS followed_VBN
        by_IN latency_NN [_NN 32_CD 33_CD ]_NN ._. This_DT latency_NN is_VBZ characterized_VBN by_IN the_DT
        presence_NN of_IN the_DT viral_JJ genome_NN whereas_IN infectious_JJ viral_JJ
        particles_NNS could_MD not_RB be_VB detected_VBN ._. In_IN addition_NN it_PRP was_VBD
        possible_JJ to_TO reactivate_NN virus_NN either_CC 
        in_IN vivo_NN or_CC 
        in_IN vitro_NN from_IN tissue_NN explants_NNS ._. While_IN
        there_EX are_VBP several_JJ lines_NNS of_IN evidence_NN to_TO suggest_VB that_IN the_DT
        immune_JJ system_NN ,_, or_CC its_PRP$ absence_NN ,_, plays_VBZ a_DT role_NN in_IN MCMV_NNP
        reactivation_NN from_IN latency_NN [_NN 34_CD 35_CD ]_NN the_DT mechanism_NN is_VBZ not_RB
        known_VBN ._. Latent_NNP CMV_NNP in_IN many_JJ organs_NNS can_MD be_VB reactivated_VBN from_IN
        its_PRP$ dormant_JJ state_NN by_IN several_JJ means_NNS of_IN immunosuppression_NN ,_,
        including_VBG transmission_NN from_IN donors_NNS to_TO immunosuppressed_JJ
        recipients_NNS of_IN transplants_NNS ,_, and_CC blood_NN transfusion_NN ._.
        Prior_RB studies_VBZ describe_VBP development_NN of_IN MCMV_NNP associated_VBN
        vascular_NN lesions_NNS in_IN large_JJ arterial_NN vessels_NNS of_IN mice_NNS ._. The_DT
        i_NNP ._. p_NN ._. injection_NN of_IN suckling_VBG mice_NNS induces_VBZ vascular_NN lesions_NNS in_IN
        the_DT aorta_NN and_CC pulmonary_JJ artery_NN ,_, which_WDT are_VBP characterized_VBN by_IN
        cellular_JJ infiltrates_NNS containing_VBG T-_NNP lymphocytes_NNS [_NN 36_CD ]_NN ._. A_DT
        more_RBR recent_JJ study_NN describes_VBZ the_DT development_NN of_IN MCMV_NNP induced_VBD
        vascular_NN lesions_NNS in_IN the_DT aorta_NN of_IN both_DT immunocompetent_NN mice_NNS
        and_CC those_DT lacking_VBG IFN-γ_NNP responsiveness_NNS where_WRB IFN-γ_NNP is_VBZ
        determined_VBN to_TO be_VB a_DT major_JJ antiviral_JJ factor_NN preventing_VBG the_DT
        long_JJ term_NN persistence_NN of_IN aortic_JJ vascular_NN lesions_NNS [_NN 18_CD ]_NN ._.
        The_DT present_JJ study_NN focused_VBN on_IN neointima_NN formation_NN ,_, which_WDT was_VBD
        seen_VBN only_RB in_IN immunocompromised_JJ mice_NNS ._. Our_PRP$ results_NNS indicated_VBD
        presence_NN of_IN both_DT CD_NNP 4_CD +_NN helper_NN ,_, and_CC CD_NNP 8_CD +_NN cytotoxic_JJ
        T-_NNP lymphocytes_NNS in_IN the_DT adventitia_NN of_IN the_DT affected_VBN arteries_NNS ._.
        Significant_JJ portion_NN of_IN these_DT T-_NNP lymphocytes_NNS are_VBP γ_NN /_NN δ-_NN TCR_NNP
        +_NN This_DT subpopulation_NN of_IN lymphocytes_NNS has_VBZ been_VBN identified_VBN as_IN
        part_NN of_IN the_DT pathogenesis_NNS of_IN autoimmune_JJ diseases_NNS ._. For_IN
        example_NN ,_, it_PRP has_VBZ been_VBN shown_VBN that_DT γ_NN /_NN δ-_NN TCR_NNP +_NN lymphocytes_NNS from_IN
        SSc_NNP patients_NNS recognize_VBP and_CC lyse_NN endothelial_NN cells_NNS at_IN a_DT
        significantly_RB higher_JJR rate_NN then_RB γ_NN /_NN δ_NN cells_NNS isolated_VBN from_IN
        control_NN subjects_NNS [_NN 16_CD ]_NN ._. Also_RB ,_, a_DT recent_JJ study_NN indicates_VBZ
        that_DT γ_NN /_NN δ-_NN TCR_NNP +_NN bearing_NN lymphocytes_NNS play_VBP an_DT important_JJ role_NN in_IN
        immune_JJ response_NN of_IN immunosuppressed_JJ transplant_NN recipients_NNS
        to_TO CMV_NNP infection_NN [_NN 37_CD ]_NN ._. NK_NNP cells_NNS ,_, natural_JJ antibodies_NNS ,_, and_CC
        complement_VB ,_, potentially_RB important_JJ in_IN controlling_VBG CMV_NNP
        infection_NN ,_, await_VBP further_JJ study_NN ._.
        Growth_NN factors_NNS TGF-β_NNP ,_, and_CC PDGF_NNP are_VBP contributing_VBG factors_NNS
        in_IN vascular_NN diseases_NNS ._. TGF-β_NNP upregulates_NNS α-smooth_JJ muscle_NN
        actin_NN gene_NN transcription_NN [_NN 38_CD ]_NN ._. Since_IN we_PRP identified_VBD
        significant_JJ α-smooth_JJ muscle_NN actin_NN expression_NN in_IN our_PRP$ model_NN
        and_CC this_DT coincided_VBD with_IN the_DT expression_NN of_IN TGF-β_NNP ,_, it_PRP is_VBZ
        possible_JJ that_IN TGF-β_NNP mediates_NNS α-smooth_JJ muscle_NN actin_NN
        expression_NN in_IN our_PRP$ model_NN ._. The_DT elevated_VBD expression_NN of_IN PDGF_NNP in_IN
        our_PRP$ model_NN is_VBZ also_RB significant_JJ since_IN the_DT expression_NN of_IN these_DT
        growth_NN factors_NNS by_IN endothelial_NN cells_NNS can_MD be_VB induced_VBN by_IN
        direct_JJ immune_JJ cell_NN -_: endothelial_NN cell_NN interaction_NN ,_,
        promoting_VBG smooth_JJ muscle_NN cell_NN migration_NN and_CC proliferation_NN in_IN
        atherosclerosis_NNS [_NN 39_CD ]_NN ._. CMV_NNP ,_, as_RB well_RB as_IN other_JJ viruses_NNS ,_,
        induces_VBZ expression_NN of_IN a_DT number_NN of_IN cytokines_NNS and_CC growth_NN
        factors_NNS in_IN cells_NNS 
        in_IN vitro_NN ,_, including_VBG TGF-β_NNP ,_, a_DT
        profibrogenic_JJ cytokine_NN [_NN 40_CD 41_CD ]_NN ._. MCP-_NNP 1_CD is_VBZ a_DT member_NN of_IN the_DT
        β-chemokine_JJ (_( C-C_NNP )_) family_NN [_NN 42_CD ]_NN and_CC this_DT chemokine_NN has_VBZ been_VBN
        implicated_VBN in_IN pathogenesis_NNS of_IN SSc_NNP [_NN 43_CD ]_NN ._. Our_PRP$ results_NNS
        (_( Fig_NNP ._. 6_CD )_) indicate_VBP that_IN this_DT chemokine_NN may_MD play_VB a_DT role_NN in_IN
        recruitment_NN of_IN inflammatory_JJ cells_NNS to_TO CMV_NNP infected_JJ
        vasculature_NN ._.
        We_PRP investigated_VBD the_DT role_NN of_IN apoptosis_NNS in_IN pathogenesis_NNS of_IN
        MCMV_NNP induced_VBD intimal_NN lesion_NN since_IN apoptosis_NNS of_IN virally_RB
        infected_JJ cells_NNS is_VBZ one_CD of_IN the_DT mechanisms_NNS by_IN which_WDT host_NN may_MD
        limit_VB the_DT virus_NN spread_VBD ._. The_DT presence_NN of_IN apoptotic_JJ
        T-_NNP lymphocytes_NNS has_VBZ been_VBN reported_VBN to_TO be_VB a_DT feature_NN of_IN MCMV_NNP
        infection_NN [_NN 44_CD ]_NN ._. Apoptosis_NNP of_IN vascular_NN endothelium_NN
        induced_VBN by_IN immune_JJ effectors_NNS has_VBZ been_VBN described_VBN in_IN both_DT SSc_NNP
        patient_NN vessels_NNS as_RB well_RB as_IN those_DT of_IN UCD_NNP chickens_NNS (_( one_CD of_IN
        the_DT animal_NN models_NNS for_IN SSc_NNP )_) [_NN 45_CD ]_NN ._. Recently_RB ,_, it_PRP has_VBZ been_VBN
        reported_VBN that_IN IgG_NNP autoantibodies_NNS from_IN SSc_NNP patients_NNS bind_NN CMV_NNP
        late_JJ protein_NN UL_NNP 94_CD and_CC this_DT induces_VBZ apoptosis_NNS in_IN human_JJ
        endothelial_NN cells_NNS [_NN 15_CD ]_NN ._. We_PRP detected_VBD the_DT presence_NN of_IN
        apoptotic_JJ cells_NNS in_IN the_DT intimal_NN layer_NN as_RB well_RB as_IN in_IN
        inflammatory_JJ infiltrate_VB of_IN the_DT affected_VBN aortas_NNS (_( Fig_NNP ._.
        7_CD A_DT &_CC 7_CD B_NNP )_) ._. In_IN the_DT future_JJ we_PRP will_MD ask_VB if_IN apoptosis_NNS in_IN our_PRP$
        model_NN is_VBZ induced_VBN by_IN anti-endothelial_JJ autoantibodies_NNS ,_, MCMV_NNP
        infection_NN of_IN endothelium_NN ,_, or_CC is_VBZ induced_VBN and_CC /_NN or_CC perpetuated_JJ
        by_IN inflammatory_JJ cells_NNS ._. Apoptosis_NNP of_IN vascular_NN endothelium_NN
        may_MD be_VB the_DT trigger_NN that_IN initiates_NNS the_DT uncontrolled_JJ repair_NN
        mechanism_NN characterized_VBN by_IN the_DT proliferation_NN of_IN smooth_JJ
        muscle_NN cells_NNS /_NN myofibroblasts_NNS ,_, leading_VBG to_TO the_DT development_NN of_IN
        neointima_NN in_IN MCMV_NNP induced_VBD vascular_NN disease_NN ._.
        The_DT development_NN of_IN CMV_NNP induced_VBD vasculopathies_NNS is_VBZ a_DT major_JJ
        cause_NN of_IN morbidity_NN and_CC mortality_NN in_IN immunosuppressed_JJ
        patients_NNS ._. CMV_NNP infections_NNS have_VBP been_VBN identified_VBN as_IN important_JJ
        mediator_NN of_IN organ_NN failure_NN and_CC death_NN in_IN transplant_NN
        recipients_NNS and_CC AIDS_NNP patients_NNS ._. Although_IN the_DT role_NN of_IN CMV_NNP
        infection_NN in_IN pathogenesis_NNS of_IN vascular_NN diseases_NNS in_IN
        immunocompetent_NN patients_NNS is_VBZ less_RBR clear_JJ ,_, epidemiological_JJ
        studies_NNS strongly_RB suggest_VBP that_IN chronic_NN or_CC latent_NN infections_NNS
        may_MD accelerate_VB the_DT development_NN of_IN diseases_NNS such_JJ as_IN
        atherosclerosis_NNS and_CC SSc_NNP ._. In_IN fact_NN ,_, it_PRP is_VBZ fair_JJ to_TO hypothesize_NN
        that_IN several_JJ diseases_NNS thought_VBD to_TO be_VB of_IN "_'' idiopathic_JJ "_'' origin_NN
        may_MD be_VB triggered_VBN by_IN chronic_JJ infections_NNS with_IN CMV_NNP and_CC other_JJ
        infectious_JJ agents_NNS in_IN the_DT genetically_RB susceptible_JJ host_NN ._.
        Animal_NNP models_NNS ,_, such_JJ as_IN those_DT described_VBN in_IN this_DT paper_NN ,_, will_MD
        allow_VB us_PRP to_TO better_JJR understand_VB the_DT role_NN that_IN viral_JJ
        infections_NNS play_VBP in_IN the_DT pathogenesis_NNS of_IN vascular_NN diseases_NNS ._.
        It_PRP is_VBZ crucial_JJ to_TO identify_VB factors_NNS responsible_JJ for_IN
        contributing_VBG to_TO the_DT development_NN of_IN vascular_NN pathology_NN in_IN
        order_NN to_TO develop_VB better_RBR preventive_JJ as_IN well_RB as_IN treatment_NN
        modalities_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Abbreviations_NNP
        CMV_NNP =_SYM cytomegalovirus_JJ ,_, MCMV_NNP =_SYM murine_NN cytomegalovirus_JJ ,_,
        MCP-_NNP 1_CD =_SYM monocyte_NN chemoattractant_NN protein-_NN 1_CD ,_, PCNA_NNP =_SYM
        proliferating_VBG cell_NN nuclear_JJ antigen_NN ,_, PDGF_NNP =_SYM platelet_NN derived_VBD
        growth_NN factor_NN ,_, SSc_NNP =_SYM systemic_JJ sclerosis_NN ,_, TGF-β_NNP 
        1_CD =_SYM transforming_VBG growth_NN factor-β_JJ 
        1_CD ,_, TUNEL_NNP =_SYM terminal_NN TdT-mediated_NNP dUTP_NN
        nick_NN end_NN labeling_VBG ,_, α-_NN SMA_NNP =_SYM α-smooth_JJ muscle_NN actin_NN
      
    
  
